Table 1 Baseline demographics
Demographic categories | Frequency | Percentage |
|---|---|---|
Gender | ||
Female | 8 | 27 |
Male | 22 | 73 |
Age | ||
18–24 | 5 | 17 |
25–34 | 5 | 17 |
35–44 | 3 | 10 |
45–54 | 5 | 17 |
55–64 | 4 | 13 |
65 + | 8 | 26 |
Years post-transplant | ||
< 1 | 1 | 3 |
1–5 | 9 | 30 |
6–10 | 7 | 23 |
11–15 | 3 | 10 |
16–20 | 3 | 10 |
21–25 | 6 | 20 |
+ 25 | 1 | 3 |
Donor-specific antibody positive | ||
total | 10 | 33 |
> 3 years | 8 | 27 |
Diabetes | 2 | 7 |
Renal dysfunction | ||
Kidney transplant | 3 | 10 |
eGFR > 89 | 3 | 10 |
eGFR 60–89 | 12 | 40 |
eGFR 45–59 | 10 | 33 |
eGFR 30–44 | 2 | 6 |
eGFR 15–29 | 0 | 0 |
eGFR < 15 | 0 | 0 |
Graft vascular disease | ||
None | 8 | 27 |
Mild | 18 | 60 |
Previous coronary stents | 4 | 13 |
Hypertension | 20 | 67 |
Body mass index | ||
18.5–24.9 | 6 | 20 |
25–29.9 | 14 | 47 |
30–39.9 | 10 | 33 |
Immunosuppression agents | ||
Tacrolimus and MMF | 18 | 60 |
Ciclosporin and MMF | 5 | 17 |
Calcineurin inhibitor and Azathioprine | 4 | 13 |
Calcineurin inhibitor monotherapy | 2 | 7 |
Sirolimus and MMF | 1 | 3 |
Statin | 25 | 83 |
Ezetimibe | 2 | 7 |